AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$ACH

Accendra (ACH) Q3 2026 Earnings Call Transcript

Accendra Health (ACH) reported Q3 2026 revenue of $602M, down 1% YoY, excluding impacts from a large commercial payer loss and asset sale. Adjusted EBITDA was $47.8M. CEO Kenny Gardner-Smith outlined a value creation plan to address performance issues, focusing on reversing revenue declines and improving collections. CFO Jonathan Leon highlighted liquidity strength and debt reduction.

Original reporting
finance.yahoo.com
Published Nov 6, 2026, 5:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 5:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Accendra (ACH) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ACHBearishMed
01

Why it matters

The earnings call reveals that revenue contraction and higher SG&A are eroding profitability, raising concerns about near‑term earnings momentum.

02

Market read

First disclosure of Q3 2026 results; material for traders watching healthcare equipment stocks.

03

What to watch

Management's new value‑creation plan and cost‑cutting initiatives may improve margins in 2027.

Relevance 7/10Novelty 8/10Timing: immediate, post‑call today

Background

Accendra Health provides home DME products; the company recently lost a large commercial payer contract and sold a non‑core asset.

Company-level read

Ticker impact

$ACHBearishHigh confidence
Context

Q3 2026 earnings call disclosed revenue of $602M (down 1% YoY) and net debt of $1.73B, highlighting disappointing performance and cash flow pressures.

Expected impact

likely pressure as the market prices in weaker revenue and elevated debt levels

Evidence & confidence

Management flagged underperformance, higher SG&A, and net debt increase; investors typically react negatively to such guidance.

Market effects

Sector

Home DME sector may face scrutiny as Accendra's payer loss highlights reimbursement risks.

Regional

U.S. healthcare equipment investors could see modest pullback.

Global

Limited; primarily affects U.S. small‑cap healthcare niche.

Counterpoint

What could challenge this read

If the payer loss is a one‑off and cash flow remains strong, the stock could be undervalued.

Key entities

  • Executive
    Kenny Gardner‑Smith

    Newly appointed CEO providing outlook.

  • Executive
    Jonathan Leon

    CFO presenting financial results.

Read at source← All news

Also covered by

2 outlets

Related articles

$ACHMed

Accendra Health Inc (ACH) (Q3 2026) Earnings Call Highlights: Revenue Slips 1% as Guidance

Accendra Health Inc (ACH) reported a 1% revenue decline in Q3 2026, its first annual drop, with adjusted EBITDA at $47.8M. Full-year adjusted EBITDA may be 30% below prior guidance. The company lost market share in sleep and respiratory, and faces operational challenges. Management expects to resolve commercial payer audit issues by Q4 2026 and outlined a turnaround plan for 2027. Net debt is $1.73B, with strong liquidity.

finance.yahoo.com
$ACHMedAI 8/10

Accendra Health Reports Third Quarter 2026 Financial Results

ACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Accendra Health Reports Third Quarter 2026 Financial Results ​ RICHMOND, VA – November 5, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the third quarter ended September 30, 2026. Unless otherwise noted, the results herei

SEC EDGAR 8-K
$ACHHighAI 8/10

Accendra Health (ACH) Q2 2026 Earnings Call Transcript

Accendra Health (ACH) reported Q2 2026 revenue of $613.2M, down from $681.9M YoY, and adjusted EBITDA of $60.1M, down from $96.6M. The company revised full-year revenue guidance to $2.45B-$2.55B and adjusted EBITDA to $300M-$320M, citing slower growth and collection rate issues. Total debt decreased by $385M to $1.72B. CEO Edward Pesicka announced his retirement by year-end.

aol.com
$ACHMedAI 8/10

Accendra Health (ACH) Q2 2026 Earnings Call Transcript

Accendra Health (ACH) reported Q2 2026 net revenue of $613.2 million, down from $681.9 million a year earlier, and adjusted EBITDA of $60.1 million versus $96.6 million. Full-year revenue guidance was revised to $2.45 billion to $2.55 billion and adjusted EBITDA to $300 million to $320 million. Debt fell to $1.72 billion as of June 30, 2026.

fool.com
$ACHMedAI 8/10

Accendra Health Reports Lower Q2 Revenue, Sets 2026 Guidance; Adopts Tax Asset Plan; Stock Down

Accendra Health (ACH) reported Q2 2026 revenue of $613.2 million, down from $681.9 million a year earlier, with GAAP net loss of $89.1 million ($1.16/share). Non-GAAP adjusted net loss was $14.3 million. Adjusted EBITDA fell to $60.1 million and free cash flow was -$25.1 million. The company guided FY2026 revenue $2.45-$2.55 billion and adjusted EBITDA $300-$320 million, and adopted a tax asset preservation plan.

rttnews.com